Anavex Life Sciences Corp.

NasdaqGS:AVXL Rapport sur les actions

Capitalisation boursière : US$238.2m

Anavex Life Sciences Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Terrie Kellmeyer

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur généralless than a year
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction2.7yrs
Durée moyenne du mandat des membres du conseil d'administration11.3yrs

Mises à jour récentes de la gestion

Recent updates

Nouveau récit • Mar 05

Long-Term Neurology Pipeline And Precision Medicine Work Will Support A Stronger Outlook

Catalysts About Anavex Life Sciences Anavex Life Sciences is a clinical stage biopharmaceutical company focused on oral precision medicine therapies for neurological disorders such as early Alzheimer's disease, schizophrenia related conditions, Parkinson's disease, Fragile X syndrome and Rett syndrome. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • Feb 10

Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory

Summary Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's, citing efficacy, safety, and trial design concerns. AVXL's pipeline progress is stalled, with no ongoing clinical trials beyond Compassionate Use and scant details on future development timelines. Financially, the company holds $131.7 million in cash and minimal expenses, providing a multi-year runway but limited near-term catalysts. Given the lack of progress and regulatory limbo, I upgrade AVXL from 'Strong Sell' to 'Sell' as valuation has declined substantially. Read the full article on Seeking Alpha
Article d’analyse • May 21

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 14

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Summary Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses. Given the EMA review's potential impact, I am considering a small investment, though not right now, acknowledging AVXL stock's high volatility and associated risks. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease

Summary Anavex Life Sciences' lead drug, Blarcamesine, failed to meet one of the two co-primary endpoints in its phase 2b/3 Alzheimer's trial, casting doubt on its efficacy and approval prospects. The trial's data inconsistencies, significant toxicity, and methodological flaws undermine the drug's potential for regulatory approval by the EMA. Despite a large market potential, the likelihood of approval is low, therefore we argue Anavex's fair valuation is cash basis ($1–$2 per share). Anavex's current financials show it is well-funded, but without successful trials, its future remains bleak. Read the full article on Seeking Alpha
Article d’analyse • Dec 25

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Dec 24

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Summary Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, and Alector have faced significant setbacks, including failed trials and financial struggles. Despite my previous “Sell” rating, Anavex stock has shown resilience, up over 350% in five years, and 90% year-to-date, contrasting with peers' declining fortunes. Biogen and Lilly's approved amyloid-targeting drugs have limited efficacy and safety risks, highlighting the need for alternative Alzheimer's treatments like Anavex's approach. Unfortunately, I see too many red flags waving to endorse AVXL, but time will tell — the European approval shot is a major catalyst upcoming that I am bearish on. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Anavex: EU Approval Application Is A Precipitous Moment

Summary Anavex (AVXL) has submitted an MAA for blarcamesine in Alzheimer's, a critical step that puts their molecule under regulatory scrutiny. Despite past trial failures, Anavex's Phase 2b/3 trial showed significant cognitive improvements, though it failed one co-primary endpoint. Data inconsistencies and lack of US clinical trials raise concerns, but EU approval could still be possible. The EMA's decision on blarcamesine, expected by mid-2025, will be crucial, especially given the FDA's controversial approval of Biogen's Aduhelm. Read the full article on Seeking Alpha
Seeking Alpha • Nov 11

Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease

Summary Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups. Safety profiles differ, with simufilam being safer but less effective long-term compared to blarcamesine. The latter may cause confusion and dizziness. Read the full article on Seeking Alpha
Seeking Alpha • Nov 05

Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Summary On Thursday, Oct. 31, Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 conference. This news sent the stock soaring, with an ~16% increase in price. I take a look at the new data and share my thoughts here. Read the full article on Seeking Alpha
Seeking Alpha • Oct 08

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Summary Anavex's lead drug, ANAVEX2-73, failed its Phase 2/3 trial for Rett syndrome, and Alzheimer's data showed questionable efficacy and concerning safety issues. The company's financial health is stable with a cash runway of about four years, but operational risks and rising costs are significant concerns. AVXL's decision to seek EU approval for ANAVEX2-73 based on limited data is perplexing, especially given the stringent regulatory environment. The overall recommendation is a "strong sell" due to poor clinical results, overvaluation, and high operational and financial risks. Read the full article on Seeking Alpha
Seeking Alpha • Jul 29

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Summary Anavex Life Sciences shared latest data from its SIGMAR-protein targeting drug Blarcamesine yesterday, in Alzheimer's Disease. On a positive note, data showed clinical decline was slowed by 38.5% in the 50-mg arm, and 34.6% in the 30mg arm. On the negative side, the secondary endpoint was not met, and there was a seemingly high number of study withdrawals. Anavex wants to file for approval of Blarcamesine in Europe this year, and also with the FDA in the US. My suspicion is that the FDA will insist on further studies, and EMA may not be convinced on efficacy and safety. Read the full article on Seeking Alpha
Article d’analyse • Jul 17

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Article d’analyse • Apr 01

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Article d’analyse • Sep 19

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

PDG

Terrie Kellmeyer

less than a year
Titularisation

Dr. Terrie Kellmeyer, Ph.D. served as Senior Vice President of Regulatory Affairs of Aardvark Therapeutics, Inc. since May 2025 until 2026. She served as Senior Vice President of Clinical Development at An...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Sandra Boenisch
Principal Financial Officer & Treasurer10.7yrsUS$555.27k0.025%
$ 59.0k
Terrie Kellmeyer
Interim Chief Executive Officerless than a yearpas de donnéespas de données
Clint Tomlinson
VP of Corporateno datapas de donnéespas de données
Adebayo Laniyonu
Senior Vice President of Nonclinical Development5.1yrspas de donnéespas de données
Kun Jin
Vice President & Head of Biostatistics3.3yrspas de donnéespas de données
Juan Carlos Lopez-Talavera
Senior VP & Head of Research and Development2.1yrspas de donnéespas de données
Wolfgang Liedtke
Senior VP & Global Head of Neurologyless than a yearpas de donnéespas de données
2.7yrs
Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de AVXL est considérée comme expérimentée (ancienneté moyenne 2.7 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jiong Ma
Independent Chairman5.1yrsUS$364.06k0%
$ 0
Jacqueline A. French
Member of the Scientific Advisory Board11.3yrspas de donnéespas de données
Paul Aisen
Member of the Scientific Advisory Board15.3yrspas de donnéespas de données
John Harrison
Member of the Scientific Advisory Board12.5yrspas de donnéespas de données
Dag Aarsland
Member of Scientific Advisory Board7.6yrspas de donnéespas de données
Ottavio Arancio
Member of the Scientific Advisory Board12.6yrspas de donnéespas de données
Tangui Maurice
Member of the Scientific Advisory Boardno datapas de donnéespas de données
Norman Relkin
Member of the Scientific Advisory Board12.1yrspas de donnéespas de données
Corinne Lasmézas
Member of the Scientific Advisory Board11.3yrspas de donnéespas de données
Daniel Weintraub
Member of the Scientific Advisory Board9.6yrspas de donnéespas de données
Peter Donhauser
Independent Director9.3yrsUS$348.06k0.0054%
$ 12.9k
Claus van der Velden
Lead Independent Director8.3yrsUS$364.06k0%
$ 0
11.3yrs
Durée moyenne de l'emploi
60yo
Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la AVXL est chevronné et expérimenté ( 11.3 années d'ancienneté moyenne).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/07 15:38
Cours de l'action en fin de journée2026/06/05 00:00
Les revenus2025/12/31
Revenus annuels2025/09/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Anavex Life Sciences Corp. est couverte par 9 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Caroline PalomequeBerenberg
Yun ZhongBrean Capital Historical (Janney Montgomery)
Jason KolbertD. Boral Capital LLC.